DK2818165T3 - Fast farmaceutisk sammensætning indeholdende 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol eller et salt deraf - Google Patents
Fast farmaceutisk sammensætning indeholdende 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol eller et salt deraf Download PDFInfo
- Publication number
- DK2818165T3 DK2818165T3 DK13752248.8T DK13752248T DK2818165T3 DK 2818165 T3 DK2818165 T3 DK 2818165T3 DK 13752248 T DK13752248 T DK 13752248T DK 2818165 T3 DK2818165 T3 DK 2818165T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzothyophen
- azetidin
- ethoxy
- propyl
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035710 | 2012-02-22 | ||
| PCT/JP2013/054268 WO2013125617A1 (ja) | 2012-02-22 | 2013-02-21 | １－（３－（２－（１－ベンゾチオフェン－５－イル）エトキシ）プロピル）アゼチジン－３－オールまたはその塩を含有する固形医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2818165T3 true DK2818165T3 (da) | 2019-06-03 |
Family
ID=49005796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13752248.8T DK2818165T3 (da) | 2012-02-22 | 2013-02-21 | Fast farmaceutisk sammensætning indeholdende 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol eller et salt deraf |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9872914B2 (enExample) |
| EP (1) | EP2818165B1 (enExample) |
| JP (1) | JP6054940B2 (enExample) |
| KR (1) | KR102070581B1 (enExample) |
| CN (1) | CN104159583B (enExample) |
| BR (1) | BR112014020434B1 (enExample) |
| CA (1) | CA2865380C (enExample) |
| DK (1) | DK2818165T3 (enExample) |
| ES (1) | ES2721666T3 (enExample) |
| IN (1) | IN2014DN06995A (enExample) |
| PL (1) | PL2818165T3 (enExample) |
| RU (1) | RU2625767C2 (enExample) |
| TR (1) | TR201907882T4 (enExample) |
| WO (1) | WO2013125617A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014026439B1 (pt) * | 2012-04-27 | 2022-05-31 | Merck Patent Gmbh | Formulação farmacêutica sob a forma de um comprimido revestido, e seu processo de preparação |
| US10646532B2 (en) | 2014-01-29 | 2020-05-12 | National Institute Of Advanced Industrial Science And Technology | Method for preparing water extract of ashwagandha leaves which has enhanced anti-cancer activity utilizing cyclodextrin, and pharmaceutical composition containing ashwagandha leaves |
| WO2017111005A1 (ja) * | 2015-12-25 | 2017-06-29 | 富山化学工業株式会社 | １－（３－（２－（１－ベンゾチオフェン－５－イル）エトキシ）プロピル）アゼチジン－３－オールまたはその塩を含む錠剤 |
| WO2018124284A1 (ja) | 2016-12-28 | 2018-07-05 | 富山化学工業株式会社 | 医薬組成物 |
| EP3563846B1 (en) * | 2016-12-28 | 2023-07-19 | FUJIFILM Toyama Chemical Co., Ltd. | Pharmaceutical composition and method for producing the same |
| WO2018124283A1 (ja) | 2016-12-28 | 2018-07-05 | 富山化学工業株式会社 | 医薬組成物 |
| WO2018124281A1 (ja) * | 2016-12-28 | 2018-07-05 | 富山化学工業株式会社 | 外用組成物 |
| JP7282028B2 (ja) * | 2017-06-02 | 2023-05-26 | 富士フイルム富山化学株式会社 | 脳萎縮予防または治療剤 |
| CN110691594A (zh) * | 2017-06-02 | 2020-01-14 | 富士胶片富山化学株式会社 | Tau蛋白病预防或治疗剂 |
| RU2728717C1 (ru) * | 2017-06-02 | 2020-07-30 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Средство для профилактики или лечения спиноцеребеллярной атаксии |
| US11541033B2 (en) | 2017-06-02 | 2023-01-03 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating Alzheimer's disease |
| KR20200003102A (ko) * | 2017-06-02 | 2020-01-08 | 후지필름 도야마 케미컬 가부시키가이샤 | 아밀로이드 β 단백질량 감소제 |
| JP7227914B2 (ja) | 2017-10-30 | 2023-02-22 | 富士フイルム富山化学株式会社 | エモパミル結合タンパク質結合剤およびその利用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100875576B1 (ko) * | 2001-04-27 | 2008-12-23 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 이소말토오스의 제조방법 및 용도 |
| JP4905752B2 (ja) | 2001-07-24 | 2012-03-28 | エスティー・ラボ株式会社 | 揮発性有機塩素化合物センサ |
| CA2464358C (en) | 2001-10-19 | 2011-05-24 | Toyama Chemical Co., Ltd. | Alkyl ether derivatives or their salts |
| US7118765B2 (en) * | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| JP4090309B2 (ja) | 2002-08-30 | 2008-05-28 | 帝人株式会社 | 全芳香族ポリエステルカーボネート系樹脂組成物 |
| ZA200508166B (en) | 2003-04-17 | 2007-03-28 | Toyama Chemical Co Ltd | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| EP1817009A2 (en) * | 2004-11-24 | 2007-08-15 | Spi Pharma, Inc. | Orally disintegrating compositions |
| SI2348022T1 (sl) | 2005-03-28 | 2013-05-31 | Toyama Chemical Co., Ltd. | Postopek proizvodnje 1-(3-(2-(1-benzotiofen-5-il)etoksi)propil)azetidin-3-ola ali soli le-tega |
| RU2397169C2 (ru) * | 2005-03-28 | 2010-08-20 | Тояма Кемикал Ко., Лтд. | Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей |
| JP2007137802A (ja) * | 2005-11-16 | 2007-06-07 | Takeda Chem Ind Ltd | 錠剤の製造法 |
| US20070196494A1 (en) * | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
| CA2650498A1 (en) * | 2006-03-31 | 2007-10-11 | Rubicon Research Private Limited | Orally disintegrating tablets |
| US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| ATE491705T1 (de) * | 2006-08-04 | 2011-01-15 | Toyama Chemical Co Ltd | Verstärker der aktivität von proteinkinase c, enthaltend ein alkyletherderivat oder ein salz davon |
| EP2583669A1 (en) * | 2007-10-10 | 2013-04-24 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
| PL2287160T3 (pl) * | 2008-05-28 | 2014-09-30 | Toyama Chemical Co Ltd | Pochodna tlenku benzotiofenu i jej sól |
-
2013
- 2013-02-21 BR BR112014020434-9A patent/BR112014020434B1/pt active IP Right Grant
- 2013-02-21 CA CA2865380A patent/CA2865380C/en active Active
- 2013-02-21 DK DK13752248.8T patent/DK2818165T3/da active
- 2013-02-21 PL PL13752248T patent/PL2818165T3/pl unknown
- 2013-02-21 KR KR1020147023511A patent/KR102070581B1/ko active Active
- 2013-02-21 WO PCT/JP2013/054268 patent/WO2013125617A1/ja not_active Ceased
- 2013-02-21 US US14/379,960 patent/US9872914B2/en active Active
- 2013-02-21 EP EP13752248.8A patent/EP2818165B1/en active Active
- 2013-02-21 ES ES13752248T patent/ES2721666T3/es active Active
- 2013-02-21 IN IN6995DEN2014 patent/IN2014DN06995A/en unknown
- 2013-02-21 RU RU2014138035A patent/RU2625767C2/ru active
- 2013-02-21 TR TR2019/07882T patent/TR201907882T4/tr unknown
- 2013-02-21 JP JP2014500753A patent/JP6054940B2/ja active Active
- 2013-02-21 CN CN201380010472.9A patent/CN104159583B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2013125617A1 (ja) | 2015-07-30 |
| KR20150001720A (ko) | 2015-01-06 |
| BR112014020434B1 (pt) | 2021-10-13 |
| EP2818165A4 (en) | 2015-07-08 |
| US20150045345A1 (en) | 2015-02-12 |
| EP2818165A1 (en) | 2014-12-31 |
| CA2865380C (en) | 2019-10-29 |
| RU2014138035A (ru) | 2016-04-10 |
| BR112014020434A2 (enExample) | 2017-06-20 |
| TR201907882T4 (tr) | 2019-06-21 |
| CN104159583A (zh) | 2014-11-19 |
| US9872914B2 (en) | 2018-01-23 |
| WO2013125617A1 (ja) | 2013-08-29 |
| CA2865380A1 (en) | 2013-08-29 |
| CN104159583B (zh) | 2018-04-13 |
| RU2625767C2 (ru) | 2017-07-18 |
| IN2014DN06995A (enExample) | 2015-04-10 |
| EP2818165B1 (en) | 2019-04-10 |
| KR102070581B1 (ko) | 2020-01-29 |
| JP6054940B2 (ja) | 2016-12-27 |
| ES2721666T3 (es) | 2019-08-02 |
| PL2818165T3 (pl) | 2019-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2818165T3 (pl) | Stała kompozycja farmaceutyczna zawierająca 1-(3-(2-(1-benzotiofen-5-ylo)etoksy)propylo)-azetydyn-3-ol albo jego sól | |
| EP2926501A4 (en) | ASYNCHRONOUS FRAMEWORK FOR IAAS MANAGEMENT | |
| SMT201700008B (it) | Composizione farmaceutica | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| EP2548549A4 (en) | EMULSION COMPOSITION | |
| EP2799514A4 (en) | PHOTOCHROME COMPOSITION | |
| ITMI20131102A1 (it) | Gestione harq-ack per subframe di dowlink non intenzionali | |
| PT2593094T (pt) | Composição aquosa contendo bromexina | |
| DK2867228T3 (da) | Fungicide heterocykliske carboxamider | |
| LT2817000T (lt) | Peroralinės dabigatrano eteksilato farmacinės kompozicijos | |
| DK3246018T3 (da) | Farmaceutisk sammensætning | |
| BR112015004936A2 (pt) | composição farmacêutica revestida contendo regorafenib | |
| EP2654736A4 (en) | NEW PHARMACEUTICAL COMPOSITION | |
| EE201300005A (et) | Ravimkoostis | |
| EP2702989A4 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
| EP2817101A4 (en) | SOLID PRODUCT DISPENSER WITH CONTROLLED RESOLUTION SPEED | |
| DK2542224T3 (da) | Oral farmaceutisk sammensætning indeholdende dabigatranetexilat | |
| DK3144319T3 (da) | Cellekultursammensætning indeholdende laminin-521 | |
| DK3395342T3 (da) | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf | |
| HUE056943T2 (hu) | CCR3 antagonistákat tartalmazó gyógyászati készítmények | |
| EP2878220A4 (en) | FOOTWEAR AND SHOE | |
| DK2815752T3 (da) | Oral farmaceutisk sammensætning | |
| EP2735414A4 (en) | CUT PROCESSING MECHANISM | |
| EP2769718A4 (en) | MEDICAL COMPOSITION | |
| EP2891692A4 (en) | Ink Composition |